Asthma Clinical Trial
— COMBIELECOfficial title:
Interest of Adding Neuromuscular Electrical Stimulation for Quadriceps Femoris and Triceps Surae Muscles to Pulmonary Rehabilitation in COPD : Randomized Clinical Trial
Patients with COPD frequently have muscle disorders. Pathogenic mechanisms generate significant pathophysiological changes in the locomotor muscles structure, leading to decreased strength, decreased endurance and limited exercise capacity. Pulmonary rehabilitation is the first choice therapy and training overall lower limb endurance is a priority. Even if the effects of pulmonary rehabilitation are no longer to be demonstrated, it is still necessary to optimize the modalities of muscular strengthening. In fact, it is recommended to associate to this global endurance training a specific strengthening of the muscles of the lower limbs. Neuromuscular electrostimulation (NMES) is a muscular strengthening technique, but this method is not used in usual practice in pulmonary rehabilitation and often only the quadriceps are concerned. In a pulmonary rehabilitation program, including sessions of NMES of the quadriceps femoris and triceps surae could increase its effectiveness. Recent studies suggest that NMES can improve muscle function, exercise tolerance, dyspnea and quality of life in COPD patients. A pilot study compared the effects of the combined quadriceps femoris and triceps surae versus quadriceps alone. The final evaluation showed a greater improvement in exercise capacity in favour of the combined NMES group. Only two studies with small numbers of patients evaluated the effect of combined quadriceps femoris and triceps surae NMES in pulmonary rehabilitation, with encouraging results in terms of functional gain. Further larger studies seem necessary to evaluate the effects of combined quadriceps femoris and triceps surae NMES in pulmonary rehabilitation. The objective of the study is to show that combined quadriceps femoris and triceps surae NMES during a pulmonary rehabilitation program provides a more significant improvement in exercise capacity compared to a standard pulmonary rehabilitation program.
Status | Recruiting |
Enrollment | 266 |
Est. completion date | November 6, 2025 |
Est. primary completion date | November 6, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient with COPD stages 2 to 4 (A to D) admitted to the Pulmonary Rehabilitation Department of the "Centre Hospitalier des Pays de Morlaix" or the "CHRU of Brest". - Patient aged 18 years or older. - Patient able to consent and having signed a consent form. Exclusion Criteria: - Patient with a history of pneumonectomy, lobectomy dated less than 6 months old - Patient with an inability to complete a respiratory rehabilitation program in its entirety - Patient under guardianship or curatorship - Person equipped with electronic devices such as pacemakers and intracardiac defibrillators. - Skin lesions and infectious foci on the area where the electrodes. - Pregnant or breastfeeding women |
Country | Name | City | State |
---|---|---|---|
France | CHU La Cavale Blanche | Brest |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Brest |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Walking distance change | Assessment of the walking distance (in meters) covered during the 6-minute walking test before and after rehabilitation (between D0 and D28± 4 days). The main endpoint is the change (in meters) between Day 0 and Day 28. | Day 0 and Day 28 | |
Secondary | Maximal isometric voluntary quadriceps strengh | Maximal isometric voluntary quadriceps strengh assessment (in newton) with handheld dynamometer | Day 0 and Day 28 | |
Secondary | Maximal isometric voluntary endurance change | Maximal isometric voluntary endurance assessment with handheld dynamometer | Day 0 and Day 28 | |
Secondary | Maximal isometric voluntary triceps surae strengh change | Maximal isometric voluntary triceps surae strengh assessment (in newton) with dynamometer type MICROFET 2 before and after rehabilitation. | Day 0 and Day 28 | |
Secondary | Exercise capacity change with the 1 min sit to stand test | Exercise capacity assessment during the 1 min sit to stand test before and after rehabilitation. | Day 0 and Day 28 | |
Secondary | Exercise capacity change with the 6 min step test | Exercise capacity assessment during the 6 min step test before and after rehabilitation. | Day 0 and Day 28 | |
Secondary | Exercise capacity change with the incremental shuttle test | Exercise capacity assessment during the incremental shuttle test before and after rehabilitation. | Day 0 and Day 28 | |
Secondary | Exercise capacity change with the endurance shuttle walk test | Exercise capacity assessment during the endurance shuttle walk test before and after rehabilitation.
before and after rehabilitation. |
Day 0 and Day 28 | |
Secondary | Dyspnea change during the 6-minute walking test | Dyspnea assessment at the end of the 6-minute walking test, with the Borg scale, before and after rehabilitation | Day 0 and Day 28 | |
Secondary | Dyspnea change during the 6-minute walking test | Dyspnea assessment at the end of the 6-minute walking test, with the Multidimensional dyspnea profile questionnaire, before and after rehabilitation | Day 0 and Day 28 | |
Secondary | Isotime dyspnea change with the endurance shuttle walk test | Isotime dyspnea assessment during the endurance shuttle walk test, using Borg scale after rehabilitation. | Day 28 | |
Secondary | Dyspnea change with the mMRC (modified Medical Research Council) scale | Assessment of dyspnea with the mMRC scale (min : 0 ; max : 4), before and after rehabilitation. | Day 0 and Day 28 | |
Secondary | Dyspnea change with the LCADL (London Chest Activity of Daily Living) questionnaire | Assessment of dyspnea with the LCADL questionnaire (better score : 0; worse score: 5), before and after rehabilitation. | Day 0 and Day 28 | |
Secondary | Dyspnea change with the Dyspnea-12 questionnaire | Assessment of dyspnea with the Dyspnea-12 questionnaire, before and after rehabilitation. | Day 0 and Day 28 | |
Secondary | Quality of life change with the St George's Respiratory Questionnaire | Quality of life assessment with the St George's Respiratory Questionnaire, before and after rehabilitation. | Day 0 and Day 28 | |
Secondary | Quality of life change with the CAT (COPD Assessment Test) Questionnaire | Quality of life assessment with COPD Assessment Test (better : 0; worse : 5), before and after rehabilitation. | Day 0 and Day 28 | |
Secondary | Fear of fall change with the FES (Falls Efficacy Scale) questionnaire | Fear of fall (FES-I Questionnaire) assessment (better : 1; worse : 4), before and after rehabilitation. | Day 0 and Day 28 | |
Secondary | Anxiety disorder change | Anxiety disorder assessment (HAD questionnaire) (better : 0; worse : 3) before and after rehabilitation. | Day 0 and Day 28 | |
Secondary | Depressive disorder change | Depressive disorder assessment (HAD questionnaire) (better : 0; worse : 3) before and after rehabilitation. | Day 0 and Day 28 | |
Secondary | Non fat mass index change | Assessment of the non fat mass index with impedancemetry , before and after rehabilitation. | Day 0 and Day 28 | |
Secondary | Self esteem change | Self esteem assessment with PSI-6 (Physical Self Inventory) questionnaire (worse :0 ; better :10) | Day 0 and Day 28 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|